Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on June 4, 2021. The filing serves as a Regulation FD disclosure regarding a proposed merger transaction and a scientific update.
Key Financial Metrics
This filing is a current report regarding a corporate event and does not contain audited financial statements, revenue, profit, cash flow, or debt metrics. The filing text does not provide a clear value for any financial performance indicators.
Material Changes and Corporate Events
- Merger Agreement: On May 16, 2021, Aerpio entered into an Agreement and Plan of Merger with Aadi Bioscience, Inc. (Aadi). Under the terms, Aadi will merge with a wholly-owned subsidiary of Aerpio, with Aadi surviving as a wholly-owned subsidiary of Aerpio.
- Scientific Update: A poster regarding Aadi's clinical data was presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.
- Transaction Status: The merger is subject to the satisfaction or waiver of conditions, including stockholder approval and the completion of a PIPE (Private Investment in Public Equity) financing.
Guidance, Risks, and Management Commentary
Management highlighted several risks associated with the proposed transaction in the forward-looking statements section:
- Approval Risks: Uncertainty regarding obtaining necessary stockholder approval and governmental approvals.
- Financing Risks: Risks related to the ability to complete the PIPE financing.
- Operational Risks: Potential for unexpected costs, delays in closing, and challenges in retaining personnel.
- Shareholder Value: Risks that the exchange ratio adjustments or CVR (Contingent Value Right) payments may result in Aerpio stockholders owning less of the combined company or receiving no value from CVRs.
Investors are urged to read the upcoming Proxy Statement for detailed information before making voting decisions.
Key Facts for Investor Verification
- Verify the final terms of the Merger Agreement and the specific exchange ratio for Aerpio and Aadi shareholders.
- Confirm the status and size of the PIPE financing required to close the transaction.
- Review the Proxy Statement for details on the CVR Agreement and potential payouts to Aerpio stockholders.
- Monitor the timeline for stockholder votes and regulatory approvals.
- Clarify the scientific data presented at ASCO 2021 and its potential impact on the combined company's pipeline.